Brunet-Dunand Severine E, Vouyovitch Cecile, Araneda Silvia, Pandey Vijay, Vidal Laurent J-P, Print Cristin, Mertani Hichem C, Lobie Peter E, Perry Jo K
Liggins Institute, University of Auckland, Private Bag, Auckland, New Zealand.
Endocrinology. 2009 Mar;150(3):1341-52. doi: 10.1210/en.2008-0608. Epub 2008 Oct 30.
Accumulating literature implicates pathological angiogenesis and lymphangiogenesis as playing key roles in tumor progression. Autocrine human growth hormone (hGH) is a wild-type orthotopically expressed oncogene for the human mammary epithelial cell. Herein we demonstrate that autocrine hGH expression in the human mammary carcinoma cell line MCF-7 stimulated the survival, proliferation, migration, and invasion of a human microvascular endothelial cell line (HMEC-1). Autocrine/paracrine hGH secreted from mammary carcinoma cells also promoted HMEC-1 in vitro tube formation as a consequence of increased vascular endothelial growth factor-A (VEGF-A) expression. Semiquantitative RT-PCR analysis demonstrated that HMEC-1 cells express both hGH and the hGH receptor (hGHR). Functional antagonism of HMEC-1-derived hGH reduced HMEC-1 survival, proliferation, migration/invasion, and tube formation in vitro. Autocrine/paracrine hGH secreted by mammary carcinoma cells increased tumor blood and lymphatic microvessel density in a xenograft model of human mammary carcinoma. Autocrine hGH is therefore a potential master regulator of tumor neovascularization, coordinating two critical processes in mammary neoplastic progression, angiogenesis and lymphangiogenesis. Consideration of hGH antagonism to inhibit angiogenic processes in mammary carcinoma is therefore warranted.
越来越多的文献表明,病理性血管生成和淋巴管生成在肿瘤进展中起关键作用。自分泌人生长激素(hGH)是人类乳腺上皮细胞的一种野生型原位表达癌基因。在此我们证明,人乳腺癌细胞系MCF-7中的自分泌hGH表达刺激了人微血管内皮细胞系(HMEC-1)的存活、增殖、迁移和侵袭。乳腺癌细胞分泌的自分泌/旁分泌hGH还由于血管内皮生长因子-A(VEGF-A)表达增加而促进了HMEC-1在体外形成管腔。半定量RT-PCR分析表明,HMEC-1细胞同时表达hGH和hGH受体(hGHR)。HMEC-1衍生的hGH的功能拮抗作用降低了HMEC-1在体外的存活、增殖、迁移/侵袭及管腔形成。在人乳腺癌异种移植模型中,乳腺癌细胞分泌的自分泌/旁分泌hGH增加了肿瘤血液和淋巴管微血管密度。因此,自分泌hGH是肿瘤新生血管形成的潜在主要调节因子,协调乳腺肿瘤进展中的两个关键过程,即血管生成和淋巴管生成。因此,有必要考虑使用hGH拮抗剂来抑制乳腺癌中的血管生成过程。